CA3059752A1 - Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic - Google Patents

Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic Download PDF

Info

Publication number
CA3059752A1
CA3059752A1 CA3059752A CA3059752A CA3059752A1 CA 3059752 A1 CA3059752 A1 CA 3059752A1 CA 3059752 A CA3059752 A CA 3059752A CA 3059752 A CA3059752 A CA 3059752A CA 3059752 A1 CA3059752 A1 CA 3059752A1
Authority
CA
Canada
Prior art keywords
cell
bcl
labeled
inhibitor
venetoclax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3059752A
Other languages
English (en)
French (fr)
Inventor
Dragan CICIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinium Pharmaceuticals Inc
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of CA3059752A1 publication Critical patent/CA3059752A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3059752A 2017-04-28 2018-04-26 Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic Pending CA3059752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491803P 2017-04-28 2017-04-28
US62/491,803 2017-04-28
PCT/US2018/029607 WO2018200841A1 (en) 2017-04-28 2018-04-26 Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

Publications (1)

Publication Number Publication Date
CA3059752A1 true CA3059752A1 (en) 2018-11-01

Family

ID=63919290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3059752A Pending CA3059752A1 (en) 2017-04-28 2018-04-26 Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

Country Status (8)

Country Link
US (4) US11364235B2 (enExample)
EP (1) EP3615047A4 (enExample)
JP (3) JP2020517704A (enExample)
CN (1) CN110612109A (enExample)
BR (1) BR112019022308A2 (enExample)
CA (1) CA3059752A1 (enExample)
MX (1) MX2019012660A (enExample)
WO (1) WO2018200841A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615047A4 (en) * 2017-04-28 2021-01-13 Actinium Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER WITH A BCL-2 INHIBITOR ASSOCIATED WITH ALPHA-EMISSING RADIOIMMUNOTHERAPY
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
JP2022516170A (ja) * 2019-01-04 2022-02-24 アクティニウム ファーマシューティカルズ インコーポレイテッド Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法
BR112022013681A2 (pt) * 2020-01-10 2022-11-16 Fusion Pharmaceuticals Inc Imunoterapia sustentada
WO2022055842A1 (en) * 2020-09-08 2022-03-17 Actinium Pharmaceuticals, Inc. Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211232B2 (en) * 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US8487131B2 (en) * 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US20160113925A1 (en) * 2014-10-22 2016-04-28 Emory University Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
TW201639573A (zh) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
PT3280729T (pt) * 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
US20180221393A1 (en) * 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP3615047A4 (en) * 2017-04-28 2021-01-13 Actinium Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER WITH A BCL-2 INHIBITOR ASSOCIATED WITH ALPHA-EMISSING RADIOIMMUNOTHERAPY

Also Published As

Publication number Publication date
EP3615047A4 (en) 2021-01-13
CN110612109A (zh) 2019-12-24
JP2020517704A (ja) 2020-06-18
US20250017919A1 (en) 2025-01-16
WO2018200841A1 (en) 2018-11-01
US12133849B2 (en) 2024-11-05
MX2019012660A (es) 2020-07-27
US20200383974A1 (en) 2020-12-10
US11844799B2 (en) 2023-12-19
US20220273648A1 (en) 2022-09-01
EP3615047A1 (en) 2020-03-04
JP2020158544A (ja) 2020-10-01
JP2023165952A (ja) 2023-11-17
US11364235B2 (en) 2022-06-21
US20240131025A1 (en) 2024-04-25
US20240226095A9 (en) 2024-07-11
BR112019022308A2 (pt) 2020-05-26

Similar Documents

Publication Publication Date Title
US12133849B2 (en) Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
US20250121105A1 (en) Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US12410249B2 (en) Low dose antibody-based methods for treating hematologic malignancies
Sharkey et al. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates
US20230302168A1 (en) Dr5 radioimmunotherapy in the treatment of solid cancers
HK40018488A (en) Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
US20240299600A1 (en) Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225
Parihar et al. Radionuclide therapy of lymphomas
EP3706785B1 (en) Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies
Kauffman Preclinical Development of Alpha-Particle Therapeutics
Jacene et al. Radionuclide therapy of lymphomas
US20100003268A1 (en) Therapy of Malignant Neoplasias
Chatterjee et al. Immunotherapeutic Strategies, Radiotherapy, and Targeted Radionuclide Therapy Approaches for the Treatment of Multiple Myeloma
Greenfield Monoclonal Antibody Therapy for Leukemia and Lymphoma
Longo Harrisons Manual of Oncology 2nd Ed.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191204

EEER Examination request

Effective date: 20191204

EEER Examination request

Effective date: 20191204

EEER Examination request

Effective date: 20191204

EEER Examination request

Effective date: 20191204